LORRAINE REBUCK: Open Payments
NPI 1669850517 · GREENEVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$623 in 28 payments from 20 companies in 2025. Trend: 2023 $3,397 · 2024 $3,275 · 2025 $623
Food & beverage: $623
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation | 3 | $67 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $54 |
| Astellas Pharma US Inc | 2 | $51 |
| Janssen Biotech, Inc. | 2 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Gilead Sciences, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $23 |
Products named: REBLOZYL, KISQALI, Trodelvy, ALUNBRIG, Onivyde, Padcev, INJECTAFER, Enhertu.
Industry payments across TN — which companies pay providers there.
